

Pamela S Becker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/591480/publications.pdf>

Version: 2024-02-01

232
papers

6,042
citations

81839

39
h-index

85498

71
g-index

233
all docs

233
docs citations

233
times ranked

7630
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. <i>Blood</i> , 2019, 133, 7-17.	0.6	1,254
2	Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 1258-1264.	0.8	223
3	A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. <i>Nature Communications</i> , 2018, 9, 42.	5.8	194
4	Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia. <i>Journal of Clinical Oncology</i> , 2010, 28, 437-444.	0.8	178
5	Cancer- and Chemotherapy-Induced Anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 628-653.	2.3	153
6	Immunofluorescence Characterization of Key Extracellular Matrix Proteins in Murine Bone Marrow In Situ. <i>Journal of Histochemistry and Cytochemistry</i> , 1998, 46, 371-377.	1.3	148
7	Adhesion receptor expression by hematopoietic cell lines and murine progenitors. <i>Experimental Hematology</i> , 1999, 27, 533-541.	0.2	134
8	Development and Validation of a Novel Acute Myeloid Leukemiaâ€“Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.	3.4	125
9	Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1520-1541.	2.3	104
10	A phase 1 study of lucatumumab, a fully human antiâ€“CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2012, 159, 58-66.	1.2	101
11	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term followâ€“up from a phase 1b study. <i>American Journal of Hematology</i> , 2021, 96, 208-217.	2.0	95
12	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 1011-1011.	0.6	91
13	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1183-1189.	2.0	89
14	Cancer- and Chemotherapy-Induced Anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 536.	2.3	86
15	A Specific Heptapeptide from a Phage Display Peptide Library Homes to Bone Marrow and Binds to Primitive Hematopoietic Stem Cells. <i>Stem Cells</i> , 2004, 22, 1030-1038.	1.4	85
16	Clofarabine with high dose cytarabine and granulocyte colonyâ€“stimulating factor (Gâ€“CSF) priming for relapsed and refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2011, 155, 182-189.	1.2	81
17	Marrow Stem Cells Shift Gene Expression and Engraftment Phenotype with Cell Cycle Transit. <i>Journal of Experimental Medicine</i> , 2003, 197, 1563-1572.	4.2	76
18	The molecular basis for the cytokine-induced defect in homing and engraftment of hematopoietic stem cells. <i>Experimental Hematology</i> , 2001, 29, 1326-1335.	0.2	70

#	ARTICLE	IF	CITATIONS
19	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 12-22.	2.3	70
20	Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood, 2009, 113, 866-874.	0.6	66
21	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 344-353.	3.2	66
22	Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer, 2011, 117, 992-1000.	2.0	64
23	Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood Advances, 2019, 3, 1939-1949.	2.5	63
24	Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. Cancer Research, 2005, 65, 358-63.	0.4	63
25	Hematopoietic Stem Cell Mobilization for Gene Therapy of Adult Patients With Severe β^2 -Thalassemia: Results of Clinical Trials Using G-CSF or Plerixafor in Splenectomized and Nonsplenectomized Subjects. Molecular Therapy, 2012, 20, 230-238.	3.7	58
26	Homing of Purified Murine Lymphohematopoietic Stem Cells: A Cytokine-Induced Defect. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 913-922.	1.8	53
27	Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1266-1290.	2.3	53
28	Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood, 2002, 100, 442-450.	0.6	50
29	Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2019, 134, 204-204.	0.6	50
30	Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2014, 124, 386-386.	0.6	50
31	Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment. Scientific World Journal, The, 2012, 2012, 1-4.	0.8	48
32	Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. Molecular Therapy, 2011, 19, 1193-1198.	3.7	45
33	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2020, 26, 6132-6140.	3.2	45
34	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome. JAMA Oncology, 2015, 1, 1120.	3.4	43
35	Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. Blood, 2019, 134, 186-198.	0.6	43
36	Anti- α -Chymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. British Journal of Haematology, 2010, 149, 706-710.	1.2	42

#	ARTICLE	IF	CITATIONS
37	Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2013, 31, 3883-3888.	0.8	42
38	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. <i>British Journal of Haematology</i> , 2017, 178, 906-913.	1.2	41
39	Radiolabel-transfer cross-linking demonstrates that protein 4.1 binds to the N-terminal region of beta spectrin and to actin in binary interactions. <i>FEBS Journal</i> , 1990, 193, 827-836.	0.2	40
40	Stem Cells and Prenatal Origin of Breast Cancer. <i>Cancer Causes and Control</i> , 2004, 15, 517-530.	0.8	40
41	Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. <i>British Journal of Haematology</i> , 2010, 148, 944-947.	1.2	40
42	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <i>Leukemia</i> , 2018, 32, 2352-2362.	3.3	39
43	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1135-1146.	0.6	39
44	Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 2032-2043.	2.5	38
45	Panobinostat: a review of trial results and future prospects in multiple myeloma. <i>Expert Review of Hematology</i> , 2015, 8, 9-18.	1.0	33
46	Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.. <i>Blood</i> , 2007, 110, 250-250.	0.6	31
47	Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. <i>Current Gene Therapy</i> , 2017, 16, 338-348.	0.9	31
48	Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. <i>Journal of Clinical Oncology</i> , 2020, 38, 4163-4174.	0.8	30
49	Feasibility Trial of Individualized Therapy for Relapsed or Refractory Acute Myeloid Leukemia Based on a High Throughput in Vitro Drug Sensitivity Assay. <i>Blood</i> , 2014, 124, 3748-3748.	0.6	30
50	Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. <i>Blood</i> , 2013, 122, 61-61.	0.6	29
51	Patient, physician and contextual factors are influential in the treatment decision making of older adults newly diagnosed with symptomatic myeloma. <i>Cancer Treatment Communications</i> , 2014, 2, 34-47.	0.4	28
52	Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. <i>Leukemia</i> , 2017, 31, 2560-2567.	3.3	28
53	High yield purification of protein 4.1 from human erythrocyte membranes. <i>Analytical Biochemistry</i> , 1983, 132, 195-201.	1.1	27
54	Sparse expression bases in cancer reveal tumor drivers. <i>Nucleic Acids Research</i> , 2015, 43, 1332-1344.	6.5	27

#	ARTICLE	IF	CITATIONS
55	A randomized study of melphalan 200â€‰mg/m ² vs 280â€‰mg/m ² as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. <i>Bone Marrow Transplantation</i> , 2016, 51, 67-71.	1.3	27
56	Variables to predict engraftment of umbilical cord blood into immunodeficient mice: usefulness of the non-obese diabetic-severe combined immunodeficient assay. <i>British Journal of Haematology</i> , 2001, 114, 211-218.	1.2	26
57	Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. <i>Lancet Haematology</i> , 2016, 3, e330-e339.	2.2	26
58	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	0.6	26
59	Successful autologous bone marrow transplant without the use of blood product support. <i>Bone Marrow Transplantation</i> , 2000, 26, 227-229.	1.3	25
60	Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. <i>British Journal of Haematology</i> , 2016, 172, 238-245.	1.2	25
61	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019, 104, 380-391.	1.7	25
62	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1226-1233.	0.6	24
63	Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. <i>Haematologica</i> , 2013, 98, 114-118.	1.7	21
64	Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015, 90, 483-486.	2.0	21
65	A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 8-17.	2.3	21
66	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 611-616.	2.5	21
67	Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies. <i>Blood</i> , 2019, 134, 264-264.	0.6	21
68	Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice. <i>British Journal of Haematology</i> , 2000, 108, 629-640.	1.2	20
69	<i>Editorial</i> : Intersecting Guidelines: Administering Erythropoiesis-Stimulating Agents to Chronic Kidney Disease Patients with Cancer. <i>Seminars in Dialysis</i> , 2009, 22, 1-4.	0.7	19
70	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Haematologica</i> , 2018, 103, e106-e109.	1.7	19
71	Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Haematologica</i> , 2019, 104, e143-e146.	1.7	19
72	Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses. <i>Blood</i> , 2018, 132, 331-331.	0.6	19

#	ARTICLE	IF	CITATIONS
73	Physical and Physiological Plasticity of Hematopoietic Stem Cells. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 934-937.	0.6	18
74	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	0.6	18
75	A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 59-65.	1.3	17
76	Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1386-1391.	2.0	17
77	A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly) Tj ETQq1 1,0,784314,rgBT /Ove	0.6	17
78	Lymphohematopoietic Stem Cell Engraftment. <i>Annals of the New York Academy of Sciences</i> , 1999, 872, 40-47.	1.8	16
79	G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2015, 90, 295-300.	2.0	16
80	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e97-e98.	1.7	16
81	Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study. <i>Blood</i> , 2011, 118, 82-82.	0.6	16
82	Multiple myeloma and Gaucher genes. <i>Genetics in Medicine</i> , 2009, 11, 134-134.	1.1	15
83	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. <i>Blood Advances</i> , 2017, 1, 2247-2256.	2.5	15
84	Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2017, 92, E75-E77.	2.0	14
85	Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation. <i>Blood</i> , 2018, 132, 297-297.	0.6	14
86	G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 2068-2068.	0.6	14
87	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3483-3483.	0.6	14
88	The Current Status of Gene Therapy in Autologous Transplantation. <i>Acta Haematologica</i> , 2005, 114, 188-197.	0.7	13
89	Adhesion receptor expression by CD34+ cells from peripheral blood or bone marrow grafts: Correlation with time to engraftment. <i>Experimental Hematology</i> , 2006, 34, 680-687.	0.2	13
90	Genetic Predisposition for Chemotherapy-Induced Neuropathy in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 783-786.	0.8	13

#	ARTICLE	IF	CITATIONS
91	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. <i>American Journal of Hematology</i> , 2018, 93, 546-552.	2.0	13
92	Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A. <i>Haematologica</i> , 2018, 103, 1806-1814.	1.7	13
93	Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function. <i>Cell Stem Cell</i> , 2022, 29, 577-592.e8.	5.2	13
94	Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation. <i>Blood Advances</i> , 2021, 5, 687-699.	2.5	12
95	A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma. <i>Blood</i> , 2008, 112, 94-94.	0.6	12
96	A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3809-3809.	0.6	12
97	The new stem cell biology. <i>Transactions of the American Clinical and Climatological Association</i> , 2002, 113, 182-206; discussion 206-7.	0.9	12
98	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Leukemia</i> , 2020, 34, 635-639.	3.3	11
99	Giant Platelets with Abnormal Surface Glycoproteins. <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 69-73.	0.3	10
100	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation. <i>American Journal of Clinical Pathology</i> , 2015, 144, 263-270.	0.4	10
101	Radioimmunotherapy consolidation using ¹³¹ I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. <i>Leukemia and Lymphoma</i> , 2016, 57, 572-576.	0.6	10
102	Gene Therapy for Fanconi Anemia in Seattle: Clinical Experience and Next Steps. <i>Blood</i> , 2016, 128, 3510-3510.	0.6	10
103	Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities. <i>Journal of Molecular Medicine</i> , 2012, 90, 1283-1294.	1.7	9
104	Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid. <i>British Journal of Haematology</i> , 2016, 172, 134-136.	1.2	9
105	Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 3882-3882.	0.6	9
106	GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study. <i>Blood</i> , 2017, 130, 894-894.	0.6	9
107	Growth factor priming in therapy of acute myelogenous leukemia. <i>Psychophysiology</i> , 2004, 3, 413-8.	1.1	9
108	JAK/STAT Pathway Inhibitors and Neurologic Toxicity. <i>JAMA Oncology</i> , 2015, 1, 651.	3.4	8

#	ARTICLE	IF	CITATIONS
109	Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2010, 116, 1885-1885.	0.6	8
110	GMI-1271, a novel E-selectin antagonist, combined with induction chemotherapy in elderly patients with untreated AML. <i>Journal of Clinical Oncology</i> , 2017, 35, 2560-2560.	0.8	8
111	Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 1411-1417.	2.0	8
112	A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age. <i>British Journal of Haematology</i> , 2015, 170, 349-355.	1.2	7
113	A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e422-e422.	2.8	7
114	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after Day 14 without further therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2717-2719.	0.6	7
115	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1023-1029.	0.6	7
116	Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study. <i>Blood</i> , 2007, 110, 1452-1452.	0.6	7
117	A Novel Small Molecule E-Selectin Inhibitor GMI-1271 Blocks Adhesion of AML Blasts to E-Selectin and Mobilizes Blood Cells in Nodscid IL2R γ Mice Engrafted with Human AML. <i>Blood</i> , 2012, 120, 4092-4092.	0.6	7
118	Management of Acute Myeloid Leukemia in the Intensive Care Setting. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 375-384.	1.3	6
119	Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2016, 23, 254-259.	1.4	6
120	90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 202-209.	1.3	6
121	High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan. <i>Blood</i> , 2019, 134, 2690-2690.	0.6	6
122	Unsupervised discovery of dynamic cell phenotypic states from transmitted light movies. <i>PLoS Computational Biology</i> , 2021, 17, e1009626.	1.5	6
123	The Role of Biosimilars. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 626-629.	2.3	5
124	Donor-derived acute promyelocytic leukemia presenting as myeloid sarcoma in a transplanted kidney. <i>Leukemia</i> , 2020, 34, 2776-2779.	3.3	5
125	KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 602-609.	0.2	5
126	High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 180-180.	0.6	5

#	ARTICLE	IF	CITATIONS
127	Transfer of the Multidrug Resistance Gene, MDR-1, to Hematopoietic Progenitors from a Patient with Transformed Large Cell Lymphoma, and Demonstration of In Vivo Chemotherapy Protection with Dose Escalating Chemotherapy.. Blood, 2004, 104, 5278-5278.	0.6	5
128	Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo. Blood, 2008, 112, 858-858.	0.6	5
129	Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS). Blood, 2011, 118, 2772-2772.	0.6	5
130	A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. Blood, 2016, 128, 4049-4049.	0.6	5
131	A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma. Blood, 2017, 130, 910-910.	0.6	5
132	GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML.. Journal of Clinical Oncology, 2017, 35, 2520-2520.	0.8	5
133	Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, 7027-7027.	0.8	5
134	Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. Leukemia Research, 2011, 35, e164-e166.	0.4	4
135	Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM). Biology of Blood and Marrow Transplantation, 2013, 19, S154.	2.0	4
136	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. Haematologica, 2021, 106, 2114-2120.	1.7	4
137	Regimenâ€”intensity per countâ€”recovery and hospitalization index: A new tool to assign regimen intensity for AML. Cancer Medicine, 2020, 9, 6515-6523.	1.3	4
138	Envelope-Specific Adaptive Immunity following Transplantation of Hematopoietic Stem Cells Modified with VSV-G Lentivirus. Molecular Therapy - Methods and Clinical Development, 2020, 19, 438-446.	1.8	4
139	High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma. JCO Precision Oncology, 2021, 5, 602-612.	1.5	4
140	Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms. Blood, 2019, 134, 1364-1364.	0.6	4
141	CD38 Status of CD34+ Myeloblasts, but Not Side Population (SP) Frequency, Predicts Initial Response to Induction Therapy In Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).. Blood, 2010, 116, 1056-1056.	0.6	4
142	Immune defects in a mouse model of <sc>F</sc>anconi anaemia. British Journal of Haematology, 2012, 159, 246-250.	1.2	3
143	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. Haematologica, 2015, 100, e254-e256.	1.7	3
144	Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. Acta Haematologica, 2017, 137, 123-131.	0.7	3

#	ARTICLE	IF	CITATIONS
145	E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML. Blood, 2018, 132, 1513-1513.	0.6	3
146	High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma. Blood, 2019, 134, 1902-1902.	0.6	3
147	Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML). Blood, 2019, 134, 260-260.	0.6	3
148	The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia. Blood, 2012, 120, 1418-1418.	0.6	3
149	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). Leukemia Research Reports, 2013, 2, 26-28.	0.2	2
150	Controversies Regarding Use of Myeloid Growth Factors in Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1551-1557.	2.3	2
151	Case of Chemotherapy-Refractory, RAS-Mutated Chronic Myelomonocytic Leukemia Responsive to Single-Agent Trametinib Based on Results From a High-Throughput Drug Screen. JCO Precision Oncology, 2020, 4, 1367-1373.	1.5	2
152	Randomized phase 1 study of sequential (â€œprimedâ€œ) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. Leukemia and Lymphoma, 2020, 61, 1728-1731.	0.6	2
153	Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial. Blood, 2018, 132, 1419-1419.	0.6	2
154	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. Blood, 2018, 132, 207-207.	0.6	2
155	Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Blood, 2019, 134, 230-230.	0.6	2
156	Infusion of â€œoff-the-shelfâ€œ Third Party Ex Vivo Expanded Cord Blood Progenitor Cells As Supportive Care Following Clofarabine with High Dose Cytarabine and Granulocyte Colony-Stimulating Factor Priming for the Treatment of AML. Blood, 2011, 118, 3640-3640.	0.6	2
157	Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay. Blood, 2013, 122, 483-483.	0.6	2
158	Outcome of Multiple Myeloma Patients Treated with Carrd-PACE Chemomobilization: A Single-Center Experience. Blood, 2016, 128, 3377-3377.	0.6	2
159	Clonal Hematopoiesis: The Seeds of Leukemia or Innocuous Bystander?. , 2016, 13, ,		2
160	Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing. Leukemia Research, 2022, 115, 106822.	0.4	2
161	Coverage of bone marrow transplant patients: A survey of American and Canadian institutions. Biology of Blood and Marrow Transplantation, 1998, 4, 49-56.	2.0	1
162	A model for prediction of <i><sc>FLT</sc></i>³ <i><sc>ITD</sc></i> and <i><sc>NPM</sc></i>¹ (without) Tj ETQq0 0 0 rgBT /Overlo leukaemia. British Journal of Haematology, 2013, 163, 130-132.	1.2	1

#	ARTICLE	IF	CITATIONS
163	Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. <i>British Journal of Haematology</i> , 2014, 166, 375-381.	1.2	1
164	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. <i>Leukemia and Lymphoma</i> , 2016, 57, 1205-1207.	0.6	1
165	Need for routine examination of left ventricular ejection fraction in patients with AML. <i>Leukemia</i> , 2020, 34, 1169-1171.	3.3	1
166	Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium. <i>Blood</i> , 2018, 132, 2710-2710.	0.6	1
167	From Bone Marrow to Mobilized Peripheral Blood Stem Cells: The Circuitous Path to Clinical Gene Therapy for Fanconi Anemia. <i>Blood</i> , 2018, 132, 2208-2208.	0.6	1
168	High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 1885-1885.	0.6	1
169	Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2964-2964.	0.6	1
170	An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).. <i>Blood</i> , 2009, 114, 2765-2765.	0.6	1
171	Randomized Comparison of Melphalan 200 Mg/m ² v. 280 Mg/m ² As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 2009-2009.	0.6	1
172	Lenalidomide Is Effective Therapy for Relapse After Allogeneic Stem Cell Transplant for Multiple Myeloma.. <i>Blood</i> , 2012, 120, 3064-3064.	0.6	1
173	Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. <i>Blood</i> , 2013, 122, 5002-5002.	0.6	1
174	Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2014, 124, 3732-3732.	0.6	1
175	Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality. <i>Blood</i> , 2014, 124, 994-994.	0.6	1
176	A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2016, 128, 1068-1068.	0.6	1
177	Age-Related Changes in the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment Correlate with Response to Treatment and Survival: A Role for L-Selectin. <i>Blood</i> , 2016, 128, 5063-5063.	0.6	1
178	Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.. <i>Blood</i> , 2009, 114, 2658-2658.	0.6	1
179	Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.. <i>Blood</i> , 2010, 116, 1065-1065.	0.6	1
180	Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. <i>Blood</i> , 2012, 120, 3594-3594.	0.6	1

#	ARTICLE	IF	CITATIONS
181	A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS). Blood, 2013, 122, 3926-3926.	0.6	1
182	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study. Blood, 2014, 124, 3730-3730.	0.6	1
183	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2018, 132, 3263-3263.	0.6	1
184	Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia. Blood, 2018, 132, 3992-3992.	0.6	1
185	A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia. Blood, 2019, 134, 2650-2650.	0.6	1
186	A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia. Blood, 2019, 134, 1269-1269.	0.6	1
187	Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia. Blood, 2020, 136, 12-13.	0.6	1
188	Optimizing Stem Cell Mobilization: Lessons Learned. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1443-1449.	2.3	0
189	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e633-e635.	0.2	0
190	Baseline characteristics of patients with Gaucher disease enrolled in the taliglucerase alfa surveillance (TALIAS) registry. Molecular Genetics and Metabolism, 2019, 126, S143.	0.5	0
191	Inhibition of $\alpha_5\beta_1$ Integrin Disrupts Adhesion and Enhances Chemotherapy Effect in Multiple Myeloma Cells.. Blood, 2007, 110, 4805-4805.	0.6	0
192	Correction of Fanconi Anemia Group A in Primary Human and Murine Hematopoietic Progenitors with a Clinical Lentiviral Vector. Blood, 2008, 112, 2357-2357.	0.6	0
193	Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.. Blood, 2009, 114, 4332-4332.	0.6	0
194	Limitations of G-CSF Mobilization in Splenectomized Patients with Beta-Thalassemia Major: Implications for Thalassemia Gene Therapy.. Blood, 2009, 114, 2150-2150.	0.6	0
195	Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2R β ^{-/-} / α ^{-/-} Xenograft and Confer Susceptibility to Cytarabine. Blood, 2011, 118, 579-579.	0.6	0
196	NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML). Blood, 2012, 120, 1479-1479.	0.6	0
197	A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma. Blood, 2012, 120, 5038-5038.	0.6	0
198	Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.. Blood, 2012, 120, 2598-2598.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Morphology Vs. Multiparameter Flow Cytometry in Evaluation of AML in Cerebrospinal Fluid (CSF).. Blood, 2012, 120, 2499-2499.	0.6	0
200	Improved Stem Cell Transplant Related Mortality for AL Amyloidosis At a Single Transplant Center. Blood, 2012, 120, 2016-2016.	0.6	0
201	A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.. Blood, 2012, 120, 2590-2590.	0.6	0
202	The Use of Day 14 Bone Marrow Characteristics in the Decision to Pursue a Second Course of Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia.. Blood, 2012, 120, 2596-2596.	0.6	0
203	Double Cord Versus Haploidentical: Which Alternative Donor Source is Better?. , 2013, 10, .		0
204	A New Ripple for Mpl: Eltrombopag for Aplastic Anemia. , 2013, 10, .		0
205	131I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission. Blood, 2013, 122, 1644-1644.	0.6	0
206	Proof-Of-Concept Study For Precision Medicine With Chromosome Genomic Array Testing (CGAT) For Drug Sensitivity Screening In Acute Myeloid Leukemia. Blood, 2013, 122, 2578-2578.	0.6	0
207	Cost and Utilization Of Stored Autologous PBSC To Support Tandem ASCT In MM Patients In The Era Of Novel Agent Therapy. Blood, 2013, 122, 4507-4507.	0.6	0
208	MLL Fusions Sustain Leukemia Through NFĀB. , 2014, 11, .		0
209	Not Just for GIST: A New FLT3 Inhibitor Active in Kinase Domain Mutated AML. , 2014, 11, .		0
210	The Fountain of Youth for Aging Stem Cells. , 2014, 11, .		0
211	Targeted Ultra-Deep High Accuracy Sequencing of Pre-Treatment AML Reveals a Diversity of Mutational Phenotypes and Evidence of Preexisting Relapse-Associated Subclones. Blood, 2014, 124, 2372-2372.	0.6	0
212	A New Crystal Ball: Day-30 Mutation Analysis after AML Induction. , 2015, 12, .		0
213	Shattered Chromosomes: A Cataclysmic Origin of Cancer. , 2015, 12, .		0
214	Up Close and Personal: Implanted Devices for Chemotherapy Testing of Tumors in Patients. , 2015, 12, .		0
215	Time to Minimal Residual Disease (MRD) Negativity Is Independently Predictive of Outcome in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD. Blood, 2015, 126, 2498-2498.	0.6	0
216	Mini-Chromosome Maintenance (MCM) DNA Helicase Genes Influence Acute Myeloid Leukemia (AML) Replication and Response to Chemotherapy-Induced DNA Damage. Blood, 2015, 126, 3629-3629.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Toward Individualized Therapy: Correlation of Mutation Analysis with in Vitro high Throughput Drug Sensitivity Testing in New Diagnosis and Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3851-3851.	0.6	0
218	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 1339-1339.	0.6	0
219	A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study. <i>Blood</i> , 2016, 128, 2787-2787.	0.6	0
220	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. <i>Blood</i> , 2016, 128, 2792-2792.	0.6	0
221	A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4043-4043.	0.6	0
222	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 1064-1064.	0.6	0
223	Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis. <i>Blood</i> , 2018, 132, 198-198.	0.6	0
224	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018, 132, 1388-1388.	0.6	0
225	Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model. <i>Blood</i> , 2018, 132, 3986-3986.	0.6	0
226	Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study. <i>Blood</i> , 2018, 132, 2954-2954.	0.6	0
227	Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 1317-1317.	0.6	0
228	Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count. <i>Blood</i> , 2019, 134, 2692-2692.	0.6	0
229	Loss of Lamin B1 in Myeloid Neoplasms with 5q Deletion Causes Myeloid-Biased Hematopoiesis and Pelger-Huet Nuclear Anomaly. <i>Blood</i> , 2021, 138, 502-502.	0.6	0
230	Custom High Throughput Drug Sensitivity Assay Reveals Therapeutic Options for Chronic Myeloid Leukemia Patients Resistant to or Intolerant of Tyrosine Kinase Inhibitors. <i>Blood</i> , 2021, 138, 268-268.	0.6	0
231	Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies. <i>Leukemia</i> , 2022, , .	3.3	0
232	Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm. <i>Leukemia</i> , 2022, , .	3.3	0